Adoptive T-cell therapy of B-cell malignancies: Conventional and physiological chimeric antigen receptors

Cancer Letters

Volumn 316, Issue 1, 2012, Pages 1-5

  Liu, Lin ^a   Sun, Meili ^b   Wang, Zhehai ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^b JINAN CENTRAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

B cell malignancy; Chimeric antigen receptor; Immunotherapy; T cell

Indexed keywords

CD19 ANTIGEN; CD20 ANTIBODY; CD28 ANTIGEN; CD70 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE T CELL THERAPY; ANTIGEN EXPRESSION; ANTIGEN FUNCTION; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE; B LYMPHOCYTE MALIGNANCY; CANCER IMMUNOTHERAPY; CELL THERAPY; DRUG EFFICACY; DRUG SAFETY; HEMATOLOGIC MALIGNANCY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SINGLE DRUG DOSE; T LYMPHOCYTE; TREATMENT RESPONSE;

EID: 84855350845     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.10.027     Document Type: Review

References (47)

1. Eshhar Z. Adoptive cancer immunotherapy using genetically engineered designer T-cells: first steps into the clinic. Curr. Opin. Mol. Ther. 2010, 12:55-63.
2. Cartellieri M., Bachmann M., Feldmann A., et al. Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J. Biomed. Biotechnol. 2010, 2010:956304.
3. Quintás-Cardama A., Wierda W., O'Brien S. Investigational immunotherapeutics for B-cell malignancies. J. Clin. Oncol. 2010, 28:884-892.
4. Leen A.M., Rooney C.M., Foster A.E. Improving T cell therapy for cancer. Annu. Rev. Immunol. 2007, 25:243-265.
5. Irving B.A., Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell 1991, 64:891-901.
6. Eshhar Z., Waks T., Gross G., et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 1993, 90:720-724.
7. Kershaw M.H., Westwood J.A., Parker L.L., et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 2006, 12:6106-6115.
8. Park J.R., Digiusto D.L., Slovak M., et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol. Ther. 2007, 15:825-833.
9. Lamers C.H.J., Sleijfer S., Vulto A.G., et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 2006, 24:e20-e22.
10. Till B.G., Jensen M.C., Wang J., et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008, 112:2261-2271.
11. Brocker T., Karjalainen K. Signals through T cell receptor-z chain alone are insufficient to prime resting T lymphocytes. J. Exp. Med. 1995, 181:1653-1659.
12. Kochenderfer J.N., Wilson W.H., Janik J.E., et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010, 116:4099-4102.
13. Kowolik C.M., Topp M.S., Gonzalez S., et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006, 66:10995-11004.
14. Hombach A., Wieczarkowiecz A., Marquardt T., et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J. Immunol. 2001, 167:6123-6131.
15. Finney H.M., Akbar A.N., Lawson A.D. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J. Immunol. 2004, 172:104-113.
16. Pulè M.A., Straathof K.C., Dotti G., et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. 2005, 12:933-941.
17. Carpenito C., Milone M.C., Hassan R., et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 2009, 106:3360-3365.
18. Tammana S., Huang X., Wong M., et al. 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum. Gene. Ther. 2010, 21:75-86.
19. Zhong X.S., Matsushita M., Plotkin J., et al. Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. Mol. Ther. 2010, 18:413-420.
20. Morgan R.A., Yang J.C., Kitano M., et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 2010, 18:843-851.
21. Sinn P.L., Sauter S.L., McCray P.B. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors-design, biosafety, and production. Gene Ther. 2005, 12:1089-1098.
22. Zhou X., Cui Y., Huang X., et al. Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells. Hum. Gene. Ther. 2003, 14:1089-1105.
23. Singh H., Manuri P.R., Olivares S., et al. Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system. Cancer Res. 2008, 68:2961-2971.
24. Zhao Y., Zheng Z., Cohen C.J., et al. High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 2006, 13:151-159.
25. Brentjens R.J. Novel approaches to immunotherapy for B-cell malignancies. Curr. Hematol. Rep. 2005, 4:64-72.
26. Nadler L.M., Anderson K.C., Marti G., et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J. Immunol. 1983, 131:244-250.
27. Brentjens R.J., Latouche J.B., Santos E., et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat. Med. 2003, 9:279-286.
28. Brentjens R.J., Santos E., Nikhamin Y., et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 2007, 13:5426-5435.
29. Loskog A., Giandomenico V., Rossig C., et al. Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 2006, 20:1819-1828.
30. Savoldo B., Ramos C.A., Liu E., et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 2011, 121:1822-1826.
31. Song D.G., Ye Q., Carpenito C., et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T Cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 2011, 71:4617-4627.
32. Imai C., Mihara K., Andreansky M., et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 2004, 18:676-684.
33. Milone M.C., Fish J.D., Carpenito C., et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 2009, 17:1453-1464.
34. Porter D.L., Levine B.L., Kalos M., et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New Engl. J. Med. 2011, 365:725-733.
35. Koehler P., Schmidt P., Hombach A.A., et al. Engineered T cells for the adoptive therapy of B-cell chronic lymphocytic leukaemia. Adv. Hematol. 2012, 2012:595060.
36. Shan D., Ledbetter J.A., Press O.W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998, 91:1644-1652.
37. Jensen M., Tan G., Forman S., et al. CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy. Biol. Blood Marrow Transplant. 1998, 4:75-83.
38. Jensen M.C., Cooper L.J., Wu A.M., et al. Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy 2003, 5:131-138.
39. Wang J., Jensen M., Lin Y., et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum. Gene. Ther. 2007, 18:712-725.
40. Grewal I.S. CD70 as a therapeutic target in human malignancies. Expert. Opin. Ther. Targets 2008, 12:341-351.
41. Shaffer D.R., Savoldo B., Yi Z., et al. T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood 2011, 117:4304-4314.
42. Salih H.R., Antropius H., Gieseke F., et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003, 102:1389-1396.
43. Zhang T., Lemoi B.A., Sentman C.L. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 2005, 106:1544-1551.
44. Markley J.C., Sadelain M. IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. Blood 2010, 115:3508-3519.
45. Di Stasi A., De Angelis B., Rooney C.M., et al. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009, 113:6392-6402.
46. Lee J.C., Hayman E., Pegram H.J., et al. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 2011, 71:2871-2881.
47. Hoyos V., Savoldo B., Quintarelli C., et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010, 24:1160-1170.